



I.W.
1634

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q91925

Jin-Soo KIM, et al.

Appln. No.: 10/559,806

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: December 8, 2005

For: TRANSDUCIBLE DNA-BINDING PROTEINS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. H. HARADA et al., "Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells", *Cancer Research*, Vol. 62, April 1, 2002, pp. 2013-2018.
2. H. WU et al., "Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain", *Neuroscience Research*, Vol. 47, 2003, pp. 131-135.
3. T. TAKENOBU et al., "Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells", *Molecular Cancer Therapeutics*, Vol. 1, October 2002, pp. 1043-1049.

Jin-Soo KIM, et al.
U.S. Appln. No.: 10/559,806
INFORMATION DISCLOSURE STATEMENT

4. A. HO et al., "Synthetic Protein Transduction Domains: Enhanced Transduction Potential *in Vitro* and *in Vivo*", *Cancer Research*, Vol. 61, January 15, 2001, pp. 474-477.
5. A.D. FRANKEL et al., "Tat Protein from Human Immunodeficiency Virus Forms a Metal-Linked Dimer", *Science*, Vol. 240, April 1, 1988, pp. 70-73.
6. D.R. GIUS et al., "Transduced p16^{INK4a} Peptides Inhibit Hypophosphorylation of the Retinoblastoma Protein and Cell Cycle Progression Prior to Activation of Cdk2 Complexes in Late G₁¹", *Cancer Research*, Vol. 59, June 1, 1999, pp. 2577-2580.
7. E.L. Snyder and S.F. Dowdy, "Cell Penetrating Peptides in Drug Delivery", *Pharmaceutical Research*, Vol. 21, No. 3, March 2004, pp. 389-393.
8. A. VOCERO-AKBANI et al., "Transduction of Full-Length Tat Fusion Proteins Directly into Mammalian Cells: Analysis of T Cell Receptor Activation-Induced Cell Death", *Methods in Enzymology*, Vol. 322, 2000, pp. 508-521.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Jin-Soo KIM, et al.
U.S. Appln. No.: 10/559,806
INFORMATION DISCLOSURE STATEMENT

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER



John T. Callahan
Registration No. 32,607

Date: April 14, 2006

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet	1	of	1	Application Number	10/559,806
				Confirmation Number	Unknown
				Filing Date	December 8, 2005
				First Named Inventor	Jin-Soo KIM
				Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	Q91925

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		H. HARADA et al., "Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells", <i>Cancer Research</i> , Vol. 62, April 1, 2002, pp. 2013-2018	
		H. WU et al., "Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain", <i>Neuroscience Research</i> , Vol. 47, 2003, pp. 131-135	
		T. TAKENOBU et al., "Development of p53 Protein Transduction Therapy Using Membrane-permeable Peptides and the Application to Oral Cancer Cells", <i>Molecular Cancer Therapeutics</i> , Vol. 1, October 2002, pp. 1043-1049	
		A. HO et al., "Synthetic Protein Transduction Domains: Enhanced Transduction Potential <i>in Vitro</i> and <i>in Vivo</i> ", <i>Cancer Research</i> , Vol. 61, January 15, 2001, pp. 474-477	
		A.D. FRANKEL et al., "Tat Protein from Human Immunodeficiency Virus Forms a Metal-Linked Dimer", <i>Science</i> , Vol. 240, April 1, 1988, pp. 70-73	
		D.R. GIUS et al., "Transduced p16 ^{INK4a} Peptides Inhibit Hypophosphorylation of the Retinoblastoma Protein and Cell Cycle Progression Prior to Activation of Cdk2 Complexes in Late G ₁ ^{1b} ", <i>Cancer Research</i> , Vol. 59, June 1, 1999, pp. 2577-2580	
		E.L. Snyder and S.F. Dowdy, "Cell Penetrating Peptides in Drug Delivery", <i>Pharmaceutical Research</i> , Vol. 21, No. 3, March 2004, pp. 389-393	
		A. VOCERO-AKBANI et al., "Transduction of Full-Length Tat Fusion Proteins Directly into Mammalian Cells: Analysis of T Cell Receptor Activation-Induced Cell Death", <i>Methods in Enzymology</i> , Vol. 322, 2000, pp. 508-521	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.